What is it about?

In critical care settings, one of the main causes of organ failure and ultimately mortality is loss of endothelial function, which is associated with leakage of blood vessels. Here, we describe the analytical assay performance for Bioactive Adrenomedullin, IB10 sphingotest® bio-ADM®. It is a rapid point-of-care (POC) immunoassay for the quantitative in vitro determination of bioactive Adrenomedullin (bio-ADM) in human EDTA whole blood or plasma.

Featured Image

Read the Original

This page is a summary of: Analytical performance evaluation of bioactive adrenomedullin on point-of-care platform, Clinical Chemistry and Laboratory Medicine (CCLM), September 2022, De Gruyter,
DOI: 10.1515/cclm-2022-0638.
You can read the full text:

Read

Contributors

Be the first to contribute to this page